Original Article

Cancer Chemotherapy and Pharmacology

, Volume 67, Issue 2, pp 305-314

First online:

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

  • Anne M. TraynorAffiliated withUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health Email author 
  • , Maureen HewittAffiliated withUniversity of Pennsylvania
  • , Glenn LiuAffiliated withUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health
  • , Keith T. FlahertyAffiliated withUniversity of Pennsylvania
  • , Jason ClarkAffiliated withMerck Research Laboratories
  • , Steven J. FreedmanAffiliated withMerck Research LaboratoriesGlaxoSmithKline
  • , Boyd B. ScottAffiliated withMerck Research Laboratories
  • , Ann Marie LeightonAffiliated withMerck Research Laboratories
  • , Patricia A. WatsonAffiliated withMerck Research Laboratories
    • , Baiteng ZhaoAffiliated withMerck Research Laboratories
    • , Peter J. O’DwyerAffiliated withUniversity of Pennsylvania
    • , George WildingAffiliated withUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Purpose

To assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety, and tolerability of the 24-h continuous intravenous (CIV) infusion of MK-0457, a novel pan-Aurora kinase inhibitor, in patients with advanced solid tumors and to determine the bioavailability of an oral dose of 100 mg MK-0457.

Study design

MK-0457 was administered as a 24-h CIV infusion every 21 days. Dose escalation proceeded per toxicity criteria. A 100-mg oral dose was administered to seven patients 48 h prior to the CIV infusion dose of 64 mg/m2/h.

Results

Twenty-seven patients received a total of 86 infusions of MK-0457. Dose-limiting toxicity at 96 mg/m2/h included grade 4 neutropenia and grade 3 herpes zoster. The MTD was identified as 64 mg/m2/h. The most common adverse events were nausea, vomiting, diarrhea, and fatigue. Pharmacokinetic analyses revealed that CIV infusion MK-0457 had an estimated mean terminal half-life of approximately 6.6–10.2 h and that end-of-infusion concentrations and mean AUCs were approximately dose proportional. The estimated mean oral bioavailability of MK-0457 was 7.9%. One patient with advanced ovarian cancer attained prolonged stable disease for 11 months.

Conclusions

MK-0457 was well tolerated in this schedule. Almost half the patients attained stable disease. Further development of this class of agents will likely occur in combination with other anti-cancer treatments.

Keywords

Phase I Aurora kinase Serine/threonine protein kinases BCR-ABL mutations